Abstract
Purpose
To investigate protective effects of alisol B 23-acetate (AB23A) against hepatotoxity and cholestasis induced by 17α-ethinylestradiol (EE) in association with farnesoid X receptor (FXR) activation in vivo and in vitro.
Methods
The cholestatic liver injury model was established by subcutaneous injections of EE in C57BL/6 mice. Serum biomarkers, bile flow assay and H&E staining were used to identify the amelioration of cholestasis after AB23A treatment. Mice primary hepatocytes culture, gene silencing experiment, real-time PCR and Western blot assay were used to elucidate the mechanisms underlying AB23A hepatoprotection.
Results
AB23A treatment protected against liver injury induced by EE through increasing hepatic efflux and reducing uptake of bile acid via an induction in efflux transporters (Bsep and Mrp2) and an inhibition in hepatic uptake transporter (Ntcp) expression. AB23A also reduced bile acid synthesis through repressing Cyp7a1 and Cyp8b1, and increased bile acid metabolism through an induction in gene expression of Sult2a1. We further demonstrated that the changes in transporters and enzymes, as well as ameliorative liver histology in AB23A-treated mice were abrogated by FXR antagonist guggulsterone in vivo and were abrogated after FXR was silenced in vitro.
Conclusions
AB23A produces protective effects against EE-induced cholestasis, due to FXR-mediated gene regulation.
Similar content being viewed by others
Abbreviations
- AB23A:
-
Alisol B 23-acetate
- ALP:
-
Alkaline phosphatase
- Bsep:
-
Bile salt export pump
- CAR:
-
Constitutive androstane receptor
- CDCA:
-
Chenodeoxycholic acid
- Cyp7a1:
-
Cholesterol 7α-hydroxylase
- Cyp8b1:
-
Sterol-12α-hydroxylase
- EE:
-
17α-ethinylestradiol
- Fgf15:
-
fibroblast growth factor 15
- FXR:
-
Farnesoid X receptor
- GS:
-
Guggulsterone
- H&E:
-
Haematoxylin & eosin
- Mrp2:
-
Multidrug resistance-related protein 2
- Ntcp:
-
Na+/taurocholate cotransporting polypeptide
- PXR:
-
Pregnane X receptor
- Shp:
-
Small heterodimer partner
- Sult2a1:
-
Hydroxysteroid sulfotransferase 2a1
- Ugt1a1:
-
UDP-glucuronosyltransferase 1a1
References
Williamson C, Miragoli M, Sheikh Abdul Kadir S, Abu-Hayyeh S, Papacleovoulou G, Geenes V, et al. Bile acid signaling in fetal tissues: implications for intrahepatic cholestasis of pregnancy. Dig Dis. 2011;29:58–61.
Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception. 2010;82:102–12.
Vihma V, Ropponen A, Aittomaki K, Ylikorkala O, Tikkanen MJ. Postmenopausal estrogen therapy and serum estradiol fatty acid esters in women with and without previous intrahepatic cholestasis of pregnancy. Ann Med. 2004;36:393–9.
Henriquez-Hernandez LA, Flores-Morales A, Santana-Farre R, Axelson M, Nilsson P, Norstedt G, et al. Role of pituitary hormones on 17alpha-ethinylestradiol-induced cholestasis in rat. J Pharmacol Exp Ther. 2007;320:695–705.
Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81:687–93.
Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008;18:1087–95.
Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368:17–29.
Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology. 2012;142:355–65.
Fiorucci S, Mencarelli A, Distrutti E, Palladino G, Cipriani S. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr Med Chem. 2010;17:139–59.
Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 2012;56:1034–43.
Wooton-Kee CR, Coy DJ, Athippozhy AT, Zhao T, Jones BR, Vore M. Mechanisms for increased expression of cholesterol 7alpha-hydroxylase (Cyp7a1) in lactating rats. Hepatology. 2010;51:277–85.
Jiang ZY, Zhang XM, Zhang FX, Liu N, Zhao F, Zhou J, et al. A new triterpene and anti-hepatitis B virus active compounds from Alisma orientalis. Planta Med. 2006;72:951–4.
Xu YH, Zhao LJ, Li Y. Alisol B acetate induces apoptosis of SGC7901 cells via mitochondrial and phosphatidylinositol 3-kinases/Akt signaling pathways. World J Gastroenterol. 2009;15:2870–7.
Jin HG, Jin Q, Ryun Kim A, Choi H, Lee JH, Kim YS, et al. A new triterpenoid from Alisma orientale and their antibacterial effect. Arch Pharm Res. 2012;35:1919–26.
Meng Q, Chen X, Wang C, Liu Q, Sun H, Sun P, et al. Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor. Biochem Pharmacol. 2014;92:289–98.
Meng Q, Chen X, Wang C, Liu Q, Sun H, Sun P, et al. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acids homeostasis. Toxicol Appl Pharmacol. 2015;283:178–86.
Mencarelli A, Renga B, Palladino G, Distrutti E, Fiorucci S. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. Biochem Pharmacol. 2009;78:1214–23.
Klaunig JE, Goldblatt PJ, Hinton DE, Lipsky MM, Chacko J, Trump BF. Mouse liver cell culture. I. Hepatocyte isolation. In Vitro. 1981;17:913–25.
Sanchez Pozzi EJ, Crocenzi FA, Pellegrino JM, Catania VA, Luquita MG, Roma MG, et al. Ursodeoxycholate reduces ethinylestradiol glucuronidation in the rat: role in prevention of estrogen-induced cholestasis. J Pharmacol Exp Ther. 2003;306:279–86.
Corpechot C. Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol. 2012;36:70016–5.
Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53:1023–34.
Chen J, Zhao KN, Liu GB. Estrogen-induced cholestasis: pathogenesis and therapeuticimplications. Hepatogastroenterology. 2013;60:1289–96.
Boaglio AC, Zucchetti AE, Sanchez Pozzi EJ, Pellegrino JM, Ochoa JE, Mottino AD, et al. Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17beta-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010;52:1465–76.
Ruiz ML, Villanueva SS, Luquita MG, Ikushiro S, Mottino AD, Catania VA. Beneficial effect of spironolactone administration on ethynylestradiol-induced cholestasis in the rat: involvement of up-regulation of multidrug resistance-associated protein 2. Drug Metab Dispos. 2007;35:2060–6.
Alrefaiand WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007;24:1803–23.
Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, Liu J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 2006;312:233–6.
Yang H, Ramani K, Xia M, Ko KS, Li TW, Oh P, et al. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology. 2009;49:1982–91.
Nicolaou M, Andress EJ, Zolnerciks JK, Dixon PH, Williamson C, Linton KJ. Canalicular ABC transporters and liver disease. J Pathol. 2012;226:300–15.
Blazquez AG, Briz O, Romero MR, Rosales R, Monte MJ, Vaquero J, et al. Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012;81:273–83.
Gundala S, Wells LD, Milliano MT, Talkad V, Luxon BA, Neuschwander-Tetri BA. The hepatocellular bile acid transporter Ntcp facilitates uptake of the lethal mushroom toxin alpha-amanitin. Arch Toxicol. 2004;78:68–73.
Herraez E, Gonzalez-Sanchez E, Vaquero J, Romero MR, Serrano MA, Marin JJ, et al. Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol Pharm. 2012;9:2565–76.
Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127:1497–512.
Kir S, Zhang Y, Gerard RD, Kliewer SA, Mangelsdorf DJ. Nuclear receptors HNF4alpha and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem. 2012;287:41334–41.
Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005;313:604–12.
Staudinger JL, Woody S, Sun M, Cui W. Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver. Drug Metab Rev. 2013;45:48–59.
ACKNOWLEDGMENTS AND DISCLOSURES
This present study was financially supported by a grant from the National Natural Science Foundation of China (Nos. 81302826, 81273580). The authors declare that there are no conflicts of interest.
Author Contributions
Qiang Meng: Study conception and design; Drafting/revision of the work for intellectual content and contex
Xinli Chen: Acquisition, analysis of data
Changyuan Wang: Acquisition, analysis of data
Qi Liu: Drafting/revision of the work for intellectual content and context
Huijun Sun: Study conception and design
Pengyuan Sun: Acquisition, analysis of data
Xiaokui Huo: Drafting/revision of the work for intellectual content and contex
Zhihao Liu: Acquisition, analysis of data
Jihong Yao: Drafting/revision of the work for intellectual content and contex
Kexin Liu: Final approval and overall responsibility for the published work
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meng, Q., Chen, X., Wang, C. et al. Protective Effects of Alisol B 23-Acetate Via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Estrogen-Induced Cholestatic Liver Injury in Mice. Pharm Res 32, 3688–3698 (2015). https://doi.org/10.1007/s11095-015-1727-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-015-1727-x